Share Name Share Symbol Market Type Share ISIN Share Description
Deltex Medical Group LSE:DEMG London Ordinary Share GB0059337583 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.25p +8.70% 3.125p 3.00p 3.25p 3.125p 3.125p 3.125p 1,185,026 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 5.5 -2.5 -0.9 - 9.78

Deltex Medical (DEMG) Latest News (3)

More Deltex Medical News
Deltex Medical Takeover Rumours

Deltex Medical (DEMG) Share Charts

1 Year Deltex Medical Chart

1 Year Deltex Medical Chart

1 Month Deltex Medical Chart

1 Month Deltex Medical Chart

Intraday Deltex Medical Chart

Intraday Deltex Medical Chart

Deltex Medical (DEMG) Discussions and Chat

Deltex Medical Forums and Chat

Date Time Title Posts
21/9/201714:57Deltex Medical - a British success story!9,060
19/5/201714:51Deltex Medical - winner or doomed to fail? 151
14/7/201411:16Deltex Medical-Optimal Growth Stock10,005
22/3/201209:04Deltex Medical - Past, Present and Future-
07/12/201111:57Deltex Medical - More key endorsements-

Add a New Thread

Deltex Medical (DEMG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
13:24:303.08100,0003,082.60O
13:22:123.0892,4052,848.48O
13:15:303.0910,000308.75O
12:51:573.09100,0003,087.50O
12:08:113.09100,0003,087.50O
View all Deltex Medical trades in real-time

Deltex Medical (DEMG) Top Chat Posts

DateSubject
21/9/2017
09:20
Deltex Medical Daily Update: Deltex Medical Group is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker DEMG. The last closing price for Deltex Medical was 2.88p.
Deltex Medical Group has a 4 week average price of 2.88p and a 12 week average price of 2.88p.
The 1 year high share price is 5.25p while the 1 year low share price is currently 2.88p.
There are currently 313,115,807 shares in issue and the average daily traded volume is 79,516 shares. The market capitalisation of Deltex Medical Group is £9,784,868.97.
17/9/2017
23:07
mrc2u: FebSome sensible points. However, if you really don't rate management, you should sell.I am actually in two minds about management.They present well and I like what they are trying to do. But they don't ever quite deliver to plan, the NHS has been a car crash and the share price is horrible. They keep on funding the company, often themselves, but never seem to raise enough money.But every time I start to lose faith, I see that all their competitors are following them and that makes me wonder. And now DEMG seem to be moving towards following the competition.So I sold a few then I bought a few them sold then bought and somehow have an awful lot.Guess that makes me a punter!MrC
17/9/2017
12:58
february 30th: yump, I make no claims to be a salesman - you either have it or you don't. You are allowed to criticize someone for something you can't do yourself. We know that the company made crucial mistakes prior to 2012. They assumed that CardioQ would largely sell itself, helped by NICE. In other words, they were complacent. As a smaller point, they took a long time to address the usability issue. Furthermore, they always took a softly softly approaching in the UK, which clearly failed. The Webinar was quite difficult to understand, but from what I gathered, it was fairly bearish, in terms of the patchy pace of American growth. A further issue with the company is that they don't seem to be taking the issue of funding and dilution seriously enough. They miss tricks with the share price, in terms of reporting things that could help inspire confidence and discourage the selling of shares. For example, outside their website, they appear to make no mention of a recent study that highlighted the benefits of CardioQ in terms of pain management. Having said all that, it's usually when I get so negative on a share I own that it starts going up in leaps and bounds.
16/9/2017
10:37
february 30th: Deltex probably needs $5m, so that it stops living under the shadow of the next funding, which it has always done. It also needs a new management team. Of course I believe the company should be sold. The Count questioned my view, but Deltex does not have the resources to sell its products in sufficient quantity. In terms of shareholders' best interests, the share price is I think going nowhere in the foreseeable future, and I think this was underpinned by the rather downbeat webinar. Nothing is going to happen, there is nothing to look forward to. And as the company will have to raise money soon - it always has to raise money soon - the condition of the stock market and the share price matters. The market is almost certainly going to substantially correct in the next year or two, sooner than the Deltex story is going to turn bullish. This means that funds will be impossible to get hold of at a reasonable rate, and Deltex will be facing massive dilution. Shareholders might not be happy selling their shares for 6p or less, but the correction will provide better opportunities than Deltex ever did. As far as other strategies are concerned, getting rid of the current management, combined with a large fund-raising, that increases the shares in issue by at least 50%, and perhaps 100%, might be an alternative. Ideally the company's listing would shift to the US, and maybe the CEO should be young, hungry and totally familiar with the US health system - and prepared to take risks. By the way, why am I still holding? I think the only reason to buy the share, aside from any short-term trading opportunities that occasionally arise, is for the possibility of a take-over. The main asset is clearly good, but its quality is largely negated by Deltex's mediocre management. In this light, and also with possible reference to Lidco, I came across this quotation from Keith Neumeyer, who is CEO of a silver miner: "The first thing I do is look at the management team. I know that a good management team could make a marginal asset quite exciting while a poor management team could destroy a great asset".
11/9/2017
08:51
february 30th: Well, there would appear to be a trial result that the company decided not to report, except on their own website. It looked a good result, with the morphine metric being particularly impressive, and today would have been a great opportunity to mention it. I'm sure Lidco would have mentioned such a result very promptly. These things do matter, because a few pence on the share price can reduce the dilution of placings. Yet the company really doesn't seem to care about the share price, at a time when they should care. I think this is further evidence of how much the company has been hobbled by the mediocrity of its management.
11/9/2017
08:28
yump: It helps if you can read. Would you like some suggestions for other companies where the share price is at an all time low, so you can post there and make yourself look credible ? Or perhaps a new challenge... Man up, find a flyer and post negative stuff there.
08/9/2017
12:57
chrisdgb: Looking at the share price, any strength would be more than welcome.......!!!!!!!!
28/7/2017
09:18
february 30th: valueman6, looks like DEMG have the superior evidence base - there is certainly a big market out there... come on team Deltex... if you're reading this and can supercharge your S&M efforts the opportunity is huge. I think the Deltex story shows that having a good product isn't good enough. Deltex's problems I believe have a lot to do with less than brilliant management. Lidco perhaps knew that their product had things to be desired, and they might then have realized that they had to make a special effort. Deltex, by contrast, seemed to have thought that the product would to a great extent sell itself, helped by NICE. By the way, I read somewhere that you should never invest in a company that has an accountant as its CEO. Having said that, Deltex has embarked on a new strategy since the end of 2012, in terms of the US, and I suppose EP has to be judged on that. There is evidence that it might be working, but we don't know for sure. As for the share price, the company don't seem to care much about it. There are non-regulatory announcements they could make that they don't make - for example about new accounts. Also, their placings are regular and small, with little apparent urgency. Why don't they just go for one, large placing? If the market crashed in the Autumn, which it could, the Deltex share price might halve, and it would be impossible to raise money on reasonable terms. But maybe Deltex's management know something we don't? Overall, I think it would be in shareholder's best interests if the company got sold - 7-8p might not seem much, but given the extreme risks of a large market correction it would probably be for the best.
18/7/2017
13:16
arf dysg: chrisdgb, they should have done that 2 weeks ago, when Lidco's share price was higher.
21/6/2017
20:54
buywell3: Well atleast 2 trades today anyway : one trade for £917 worth and another for £529 worth, but I take your point a trade is a trade no matter how tiny. Deltex Medical Group (LSE:DEMG) Share Price Alert 3.7500 Today's low: 4.0000 Sell DEMG 4.2500 Today's high: 4.0850 Buy DEMG Last trade:4.0000 Change: - (-%) Volume:35,864 Delayed price:13:35:11 Summary News Discussion Chart... Analysis... Latest trades Time Price Volume Value 13:35:11 4 22,913 917 08:02:24 4.085 12,951 529
01/5/2014
20:34
doglover2003: -- > Feb 30th DEMG management would certainly defend the company very determinedly and would not be recommending any offer to shareholders unless of several multiples of turnover and payable 100 per cent in cash. Therefore, I think you would find that DEMG management would make the Optimise Trial a very important issue for LIDCO shareholders. Any offer by LIDCO would probably produce a re-rating of DEMG and a hammering for LIDCO share price which would make the whole takeover unworkable. Even today LIDCO failed to produce evidence in support of their technology without mentioning DEMG in the same breadth as part of the trial. As for the DEMG share price, the substantial fall in the share price took place on very modest volumes. Conversely, it would not take mega volume to move the price in the opposite direction. DL
Deltex Medical share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20170921 15:59:54